Outputs (20)

Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected (2021)
Journal Article
Gynn, L. E., Anderson, E., Robinson, G., Wexler, S. A., Upstill-Goddard, G., Cox, C., & May, J. E. (2021). Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected. Mutagenesis, 36(6), 419-428. https://doi.org/10.1093/mutage/geab033

Tumour microenvironments are hallmarked in many cancer types. In haematological malignancies, bone marrow (BM) mesenchymal stromal cells (MSC) protect malignant cells from drug-induced cytotoxicity. However, less is known about malignant impact on su... Read More about Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected.

Use of machine learning-enabled scenario-based teaching in Haematology and Biomedical Science, as a replacement and supplement to traditional tools and in-person teaching during COVID-19 (2021)
Journal Article
May, J., Anderson, E., Clark, D., & Hull, J. (2021). Use of machine learning-enabled scenario-based teaching in Haematology and Biomedical Science, as a replacement and supplement to traditional tools and in-person teaching during COVID-19. British Journal of Haematology, 193(S1), 72

One of the biggest challenges during the COVID-19 pandemic has been maintaining student engagement and providing the best learning experience with limited face-to-face (FTF) contact, and social distancing requirements. Whilst multiple tools are avail... Read More about Use of machine learning-enabled scenario-based teaching in Haematology and Biomedical Science, as a replacement and supplement to traditional tools and in-person teaching during COVID-19.

Leukaemic and bone marrow stromal cells alter cytarabine genotoxicity and cytotoxicity in favour of disease (2019)
Journal Article
May, J., Gynn, L., Anderson, E., & Robinson, G. (2019). Leukaemic and bone marrow stromal cells alter cytarabine genotoxicity and cytotoxicity in favour of disease. Mutagenesis, 34(5/6), e5. https://doi.org/10.1093/mutage/gez025

Resistance to therapy remains one of the greatest challenges in the management of the blood and bone marrow (BM) disorder, acute myeloid leukaemia (AML). This study aimed to investigate how leukaemic and BM stromal cells contribute to altered chemo-s... Read More about Leukaemic and bone marrow stromal cells alter cytarabine genotoxicity and cytotoxicity in favour of disease.

Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML). (2019)
Journal Article
Gynn, L. E., Anderson, E., Robinson, G. M., Wexler, S. A., Upstill-Goddard, G., Cox, C., …Morgan, R. G. (2019). Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML). Blood, 134(Supplement 1), 2492. https://doi.org/10.1182/blood-2019-122891

Mesenchymal stromal cells (MSC) are known to protect leukemic cells from drug-induced toxicity within the bone marrow (BM) niche, however, less is known about leukemic impact on supportive MSC. The nucleoside-analogue, cytarabine (Ara-C), is a front-... Read More about Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML)..

Intracellular cytarabine triphosphate in circulating blasts post-treatment predicts remission status in patients with acute myeloid leukemia (2019)
Journal Article
Anderson, E., Rees, B., Hull, J., Heywood, J., Preston, A., Protheroe, R., …Mehta, P. (2019). Intracellular cytarabine triphosphate in circulating blasts post-treatment predicts remission status in patients with acute myeloid leukemia. Experimental Hematology, 74, 13-18.e3. https://doi.org/10.1016/j.exphem.2019.04.005

© 2019 Cytarabine remains the backbone of therapy in acute myeloid leukemia (AML). The ability to assess intracellular cytarabine triphosphate (ara-CTP) levels in patients receiving cytarabine represents a major goal in the prediction of treatment re... Read More about Intracellular cytarabine triphosphate in circulating blasts post-treatment predicts remission status in patients with acute myeloid leukemia.

CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML (2018)
Journal Article
Anderson, E., Mehta, P., Heywood, J., Rees, B., Bone, H., Robinson, G., …Mayer, L. (2018). CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML. Leukemia Research, 74, 121-129. https://doi.org/10.1016/j.leukres.2018.08.007

© 2018 Elsevier Ltd CPX-351, a liposomal formulation co-encapsulating cytarabine and daunorubicin (DNR) in a synergistic 5:1 M ratio, has shown favourable response in newly diagnosed elderly high-risk AML. This study assessed intracellular ara-CTP le... Read More about CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.

Development of a 2D leukaemia-stroma model for analyses of chemo-toxicity protection using a novel bacterial bioluminescent biosensor (2017)
Journal Article
Gynn, L., May, J., Anderson, E., & Robinson, G. (2017). Development of a 2D leukaemia-stroma model for analyses of chemo-toxicity protection using a novel bacterial bioluminescent biosensor. Mutagenesis, 32(6), 619. https://doi.org/10.1093/mutage/gex033

This study aimed to develop a 2D leukaemia-stroma model of the bone marrow for analysis of stromal-mediated chemo-protection; known to contribute to chemotherapy resistance. The model must facilitate integration of a bioluminescent biosensor HA1 for... Read More about Development of a 2D leukaemia-stroma model for analyses of chemo-toxicity protection using a novel bacterial bioluminescent biosensor.

Rapid in vitro testing and characterization of resistance to chemotherapeutic agents daunorubicin and cytarabine in acute myeloid leukaemia (2017)
Journal Article
May, J., Steven, J., Taylor, A., Dean, S., & Anderson, E. (2017). Rapid in vitro testing and characterization of resistance to chemotherapeutic agents daunorubicin and cytarabine in acute myeloid leukaemia. Mutagenesis, 32(6), 627. https://doi.org/10.1093/mutage/gex033

Treatment success in leukaemia is impacted by patient resistance to chemotherapy including cytarabine (ara-C) and the anthracycline daunorubicin (DNR) requiring rapid pre-screening testing. DNR is converted to daunorubicinol (DNRol) by carbonyl reduc... Read More about Rapid in vitro testing and characterization of resistance to chemotherapeutic agents daunorubicin and cytarabine in acute myeloid leukaemia.

A novel biosensor for prediction of global hypomethylation by decitabine and azacytadine in leukaemic cells (2015)
Journal Article
May, J. E., Allainguillaume, J., Page, K., Stratford-Smith, C., Aruomaren, A., Alloush, H., …Anderson, E. (2015). A novel biosensor for prediction of global hypomethylation by decitabine and azacytadine in leukaemic cells. Mutagenesis, 30(6), 856. https://doi.org/10.1093/mutage/gev074

Decitabine (DAC) and azacytidine (AZA) are cytidine ana- logues and hypomethylating agents used in the manage- ment of patients with myelodysplastic syndrome (MDS), where the main goal is to prevent transformation to acute myeloid leukaemia (AML), wh... Read More about A novel biosensor for prediction of global hypomethylation by decitabine and azacytadine in leukaemic cells.

Investigation and verification of a bioluminescent biosensor for the quantitation of ara-CTP generation: A biomarker for cytosine arabinoside sensitivity in acute myeloid leukaemia (2014)
Journal Article
Graham Smith, J., Peter Fitzgerald, S., Martin, A., Ann Smith, M., Conway, M., Anderson, E., …Salisbury, V. (2014). Investigation and verification of a bioluminescent biosensor for the quantitation of ara-CTP generation: A biomarker for cytosine arabinoside sensitivity in acute myeloid leukaemia. Biosensors and Bioelectronics, 52, 345-353. https://doi.org/10.1016/j.bios.2013.09.014

A novel whole cell bacterial biosensor, which emits light in response to the active metabolite of cytosine arabinoside (ara-C, cytarabine), ara-CTP, has been investigated and verified. The biosensor has been formulated as an ex vivo assay, designed f... Read More about Investigation and verification of a bioluminescent biosensor for the quantitation of ara-CTP generation: A biomarker for cytosine arabinoside sensitivity in acute myeloid leukaemia.